CASI Stock Forecast 2025-2026
Distance to CASI Price Targets
CASI Price Momentum
10 Quality Stocks Worth Considering Now
Researching CASI Pharmaceuticals (CASI) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on CASI and similar high-potential opportunities.
Latest CASI Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, CASI has a bullish consensus with a median price target of $4.00 (ranging from $4.00 to $4.00). The overall analyst rating is Strong Buy (8.0/10). Currently trading at $2.02, the median forecast implies a 98.0% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Sean Lee at HC Wainwright & Co., projecting a 98.0% upside. Conversely, the most conservative target is provided by Sean Lee at HC Wainwright & Co., suggesting a 98.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CASI Analyst Ratings
CASI Price Target Range
Latest CASI Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CASI.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 9, 2025 | HC Wainwright & Co. | Sean Lee | Buy | Maintains | $4.00 |
| May 15, 2024 | HC Wainwright & Co. | Sean Lee | Buy | Maintains | $6.00 |
| Nov 15, 2023 | HC Wainwright & Co. | Sean Lee | Buy | Maintains | $12.00 |
| Aug 14, 2023 | HC Wainwright & Co. | Sean Lee | Buy | Reiterates | $10.00 |
| May 22, 2023 | HC Wainwright & Co. | Sean Lee | Buy | Reiterates | $10.00 |
| Nov 16, 2022 | BTIG | Justin Zelin | Buy | Maintains | $10.00 |
| Nov 15, 2022 | HC Wainwright & Co. | Sean Lee | Buy | Maintains | $10.00 |
| Aug 15, 2022 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $12.00 |
| Jun 3, 2022 | BTIG | Justin Zelin | Buy | Maintains | $21.00 |
| May 16, 2022 | HC Wainwright & Co. | Sean Lee | Buy | Maintains | $3.00 |
| May 18, 2021 | BTIG | Buy | Initiates | $0.00 | |
| May 14, 2021 | HC Wainwright & Co. | Sean Lee | Buy | Maintains | $4.00 |
| Apr 26, 2021 | Mizuho | Buy | Initiates | $0.00 | |
| Oct 23, 2020 | Oppenheimer | Outperform | Initiates | $0.00 | |
| Mar 24, 2020 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $3.50 |
| Sep 22, 2016 | Maxim Group | Buy | Initiates | $0.00 | |
| Jun 23, 2015 | H.C. Wainwright | Buy | Initiates | $0.00 |
Casi Pharmaceuticals Inc. (CASI) Competitors
The following stocks are similar to CASI Pharmaceuticals based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Casi Pharmaceuticals Inc. (CASI) Financial Data
Casi Pharmaceuticals Inc. has a market capitalization of $30.99M with a P/E ratio of -0.8x. The company generates $28.54M in trailing twelve-month revenue with a -137.6% profit margin.
Revenue growth is +94.3% quarter-over-quarter, while maintaining an operating margin of -92.5% and return on equity of -301.8%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Casi Pharmaceuticals Inc. (CASI) Business Model
About Casi Pharmaceuticals Inc.
Develops innovative cancer therapeutics.
The company generates revenue through the development and commercialization of cancer treatments, focusing on late-stage clinical trials and regulatory approvals. By leveraging strategic partnerships and distribution networks, particularly in North America and Asia, Casi Pharmaceuticals aims to deliver effective therapies to meet unmet clinical needs in oncology.
Casi Pharmaceuticals is committed to enhancing therapeutic efficacy and patient outcomes, positioning itself as a key player in advancing cancer treatment solutions within the healthcare and life sciences sectors. The company also seeks to expand its product pipeline through in-house developments and strategic acquisitions.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
233
CEO
Dr. Wei-Wu He Ph.D.
Country
China
IPO Year
1996
Website
www.casipharmaceuticals.comCasi Pharmaceuticals Inc. (CASI) Latest News & Analysis
Latest News
CASI Pharmaceuticals' board received a revised proposal from CEO Dr. Wei-Wu He to acquire its business operations in China and certain rights in Asia for $20 million, including $20 million in debt.
CASI Pharmaceuticals' CEO proposed a $20 million acquisition of its operations in China, affecting its strategic direction and potentially impacting stock valuation and investor sentiment.
CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Business and Financial Results
24 days agoCASI Pharmaceuticals (NASDAQ:CASI) reported its Q4 2024 business and financial results on March 31, 2025, and provided updates on key highlights for 2024.
CASI Pharmaceuticals' fourth-quarter results and 2024 updates can influence stock performance, indicating the company's growth, financial health, and potential future developments in biopharmaceuticals.
CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia
3 months agoCASI Pharmaceuticals has begun dosing the first patient in a Phase 1/2 trial for CID-103 aimed at treating chronic Immune Thrombocytopenia in China, marking a key milestone for the company.
The initiation of a Phase 1/2 trial for CID-103 indicates progress in CASI Pharmaceuticals' pipeline, potentially boosting investor confidence and impacting stock performance.
CASI Pharmaceuticals reported Q3 2024 results, highlighting progress in developing treatments for organ transplant rejection and autoimmune diseases, as stated by CEO Dr. Wei-Wu He.
CASI's focus on organ transplant rejection and autoimmune diseases signals potential growth areas, impacting future revenue and market positioning, which can influence investor sentiment and stock performance.
CASI Pharmaceuticals Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia
6 months agoCASI Pharmaceuticals has received approval from China's NMPA for a phase 1/2 clinical trial of CID-103 in adults with chronic Immune Thrombocytopenia, following FDA approval in May 2024.
CASI Pharmaceuticals' approval for a clinical trial in China boosts its growth prospects and market presence, potentially enhancing stock value and attracting investor interest.
CASI PHARMACEUTICALS TO PARTICIPATE IN THE 2024 H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE
7 months agoCASI Pharmaceuticals, Inc. will participate in the H.C. Wainwright Global Investment Conference, highlighting its focus on innovative therapeutic developments.
CASI Pharmaceuticals' participation in a prominent conference may indicate potential partnerships or funding opportunities, impacting its market position and stock performance.
Frequently Asked Questions About CASI Stock
What is Casi Pharmaceuticals Inc.'s (CASI) stock forecast for 2025?
Based on our analysis of 4 Wall Street analysts, Casi Pharmaceuticals Inc. (CASI) has a median price target of $4.00. The highest price target is $4.00 and the lowest is $4.00.
Is CASI stock a good investment in 2025?
According to current analyst ratings, CASI has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.02. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CASI stock?
Wall Street analysts predict CASI stock could reach $4.00 in the next 12 months. This represents a 98.0% increase from the current price of $2.02. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Casi Pharmaceuticals Inc.'s business model?
The company generates revenue through the development and commercialization of cancer treatments, focusing on late-stage clinical trials and regulatory approvals. By leveraging strategic partnerships and distribution networks, particularly in North America and Asia, Casi Pharmaceuticals aims to deliver effective therapies to meet unmet clinical needs in oncology.
What is the highest forecasted price for CASI Casi Pharmaceuticals Inc.?
The highest price target for CASI is $4.00 from Sean Lee at HC Wainwright & Co., which represents a 98.0% increase from the current price of $2.02.
What is the lowest forecasted price for CASI Casi Pharmaceuticals Inc.?
The lowest price target for CASI is $4.00 from Sean Lee at HC Wainwright & Co., which represents a 98.0% increase from the current price of $2.02.
What is the overall CASI consensus from analysts for Casi Pharmaceuticals Inc.?
The overall analyst consensus for CASI is bullish. Out of 4 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $4.00.
How accurate are CASI stock price projections?
Stock price projections, including those for Casi Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.